Neoplasm
Not recruitingStudy on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors
Belgium- Participants:18–64 years · 65+ years
- Substances:Df1001
- Sponsor:Dragonfly Therapeutics Inc.
Rare diseases
Investigational molecules
Locations

35 Gatehouse Drive, 02451-1215, United States
Dragonfly Therapeutics Inc. is active in clinical research for advanced solid tumors, including unresectable, recurrent, and metastatic disease. Its studies focus on treatment-resistant cancers where new oncology approaches are needed.
The sponsor’s portfolio includes investigational work in patients with advanced disease across selected indications, with attention to tumor control and clinical activity.
Dragonfly Therapeutics Inc. runs clinical trials in conditions such as Neoplasm, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Belgium
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.